Valuation: Allogene Therapeutics, Inc.

Market Cap 425M 381M 352M 319M 597M 40.36B 604M 4.22B 1.68B 21.16B 1.6B 1.56B 67.09B P/E 2026 *
-2.04x
P/E 2027 * -1.92x
Enterprise Value 228M 205M 189M 172M 321M 21.7B 325M 2.27B 901M 11.37B 857M 839M 36.07B EV / Sales 2026 *
61.1x
EV / Sales 2027 * 22.7x
Free-Float
88.98%
Yield 2026 *
-
Yield 2027 * -
1 day+1.65%
1 week-7.52%
Current month-23.12%
1 month-25.45%
3 months-29.71%
6 months-45.33%
Current year-10.22%
1 week 1.16
Extreme 1.16
1.33
1 month 1.16
Extreme 1.16
1.66
Current year 1.16
Extreme 1.16
4.46
1 year 1.04
Extreme 1.04
4.46
3 years 0.86
Extreme 0.8621
5.78
5 years 0.86
Extreme 0.8621
20.75
10 years 0.86
Extreme 0.8621
55
Manager TitleAgeSince
Chief Executive Officer 48 30/06/2026
Director of Finance/CFO 61 15/10/2023
Chief Tech/Sci/R&D Officer 49 27/02/2025
Director TitleAgeSince
Chairman 76 31/10/2017
Director/Board Member 66 31/05/2018
Director/Board Member 49 31/10/2017
Date Insider Type Main position Quantity % Market Cap. Importance
21/08/26 Sell

Compliance Officer

-29,697 0.0086%
01/07/26 Free

Chief Executive Officer

610,720 0.1769%
18/06/26 Free

Director

95,400 0.0276%
Change 5-day change 1-year change 3-year change Capi.($)
+1.65%-7.52%0.00%-51.38% 425M
-3.10%-4.19%+32.67%+59.47% 63.48B
+0.69%+0.20%+10.64%+80.20% 54.55B
-0.93%+1.12%+10.59%+102.44% 53.59B
-0.75%+1.38%+24.89%+50.91% 44.75B
-1.30%-4.80%+16.05%+114.76% 41.62B
+1.26%-5.26%+221.12%+900.64% 39.91B
-0.74%-4.46%+11.00%+44.65% 32.47B
+0.60%+15.04%+61.39%+51.38% 26.7B
+3.72%-6.23%+26.01%-8.28% 23.36B
Average +0.11%-1.83%+41.44%+134.48% 38.09B
Weighted average by Cap. -0.44%-1.28%+43.15%+155.57%

Financials

2026 *2027 *
Net sales 3.74M 3.36M 3.1M 2.81M 5.25M 355M 5.32M 37.16M 14.76M 186M 14.04M 13.74M 590M 12.09M 10.85M 10.02M 9.08M 16.97M 1.15B 17.18M 120M 47.69M 602M 45.37M 44.4M 1.91B
Net income -185M -166M -154M -139M -260M -17.6B -264M -1.84B -731M -9.23B -696M -681M -29.26B -220M -197M -182M -165M -309M -20.88B -313M -2.18B -867M -10.95B -825M -808M -34.71B
Net Debt -197M -176M -163M -148M -276M -18.67B -279M -1.95B -775M -9.78B -738M -722M -31.03B -150M -135M -124M -113M -211M -14.26B -214M -1.49B -593M -7.48B -564M -552M -23.71B
Projected Income Statement - Annual - Allogene Therapeutics, Inc.
Logo Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.
Employees
151
Date Price Change Volume
27/10/26 US$1.230 +1.65% 16,104,118
26/10/26 US$1.210 -3.20% 10,576,386
23/10/26 US$1.250 0.00% 8,404,821
22/10/26 US$1.250 -6.02% 8,296,760
21/10/26 US$1.330 0.00% 4,742,435
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Allogene Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
1.230USD
Average target price
9.000USD
Spread / Average Target
+631.71%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Allogene Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. ALLO Stock